Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The CPRX news feed on Stock Titan aggregates company announcements, financial updates, scientific disclosures, and investor conference appearances drawn from Catalyst’s own public communications and regulatory filings.
Readers can find earnings and financial result announcements, where Catalyst reports product revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with commentary on operating performance and business outlook. These releases often discuss factors such as organic growth in Lambert-Eaton myasthenic syndrome markets, demand in Duchenne muscular dystrophy centers of excellence, and the impact of generic competition on specific products.
The news stream also features corporate and strategic updates, including authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, and developments in clinical practice guidelines that reference conditions and therapies linked to the company’s portfolio. In addition, Catalyst regularly announces participation in major healthcare and investor conferences, providing insight into how management presents the story behind CPRX to the investment community.
For those following the scientific and patient-focused side of the business, the news includes conference presentations and advocacy initiatives, such as real-world analyses in Duchenne muscular dystrophy, research on Lambert-Eaton myasthenic syndrome, and programs like the Catalyst Advocacy Scholars Summit with academic partners. Investors, analysts, and patients can use this page to monitor how Catalyst’s rare disease strategy, clinical activities, and capital allocation decisions evolve over time. Bookmark this CPRX news page for a centralized view of the company’s key public announcements.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced on November 4, 2025 that it was named to the BioSpace 2026 Best Places to Work list for the second consecutive year, ranking 13 among 30 U.S. small employers.
The recognition reflects BioSpace's evaluation of workplace culture, career growth, leadership and innovation, based on votes and ratings from thousands of life‑science community members. Catalyst highlighted its mission to develop therapies for rare diseases and credited its team for the award. This is BioSpace's fifth Best Places to Work list.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025. Rich Daly, President and CEO, and other members of management will present.
Presentation time: 2:00 pm GMT. A live webcast will be available in the Investors section at www.catalystpharma.com, and a replay will be available for at least 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call and live webcast on Thursday, November 6, 2025 at 8:30 AM ET to discuss results and provide a business update.
Investors can join by phone (US/Canada: 877-407-8912; International: 201-689-8059) or via the webcast in the Investors section at www.catalystpharma.com. A replay of the webcast will be available on the company website for at least 30 days following the event.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced multiple scientific poster presentations and sessions for October 2025 reporting real-world and clinical analyses. Presentations include Duchenne muscular dystrophy analyses on glucocorticoid duration, respiratory decline, and adverse outcomes, plus a poster on amifampridine phosphate dosing in Lambert Eaton myasthenic syndrome.
Conferences and dates: Child Neurology Society posters on Oct 9, 2025; AANEM poster sessions on Oct 30–31, 2025; and MGFA scientific poster on Oct 29, 2025. Presenters named include Steven D Woods, Bridget McGowan, Yaacov Anziska.
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced a new $200 million share repurchase program effective from October 1, 2025, to December 31, 2026. The company plans to fund the buyback using its existing cash reserves.
As of June 30, 2025, Catalyst maintains a strong financial position with over $650 million in cash and cash equivalents and no funded debt. The repurchases may be executed through open market or privately negotiated purchases, with timing and volume depending on various market factors. The company maintains flexibility to suspend or terminate the program at any time.
Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced its participation in four upcoming investor conferences in September 2025.
The company's management team, led by CEO Richard J. Daly, will present at the Wells Fargo Healthcare Conference (Sept. 3), Cantor Global Healthcare Conference (Sept. 4), H.C. Wainwright Global Investment Conference (Sept. 8), and Baird Global Conference (Sept. 9). All presentations will be available via webcast on the company's website with replays accessible for 30 days.
Catalyst Pharmaceuticals (NASDAQ:CPRX) has reached a settlement agreement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE® (amifampridine). Under the agreement, Lupin will not market its generic version of FIRDAPSE until February 25, 2035, pending FDA approval.
The settlement resolves the litigation initiated by Catalyst and SERB S.A. in response to Lupin's Abbreviated New Drug Application (ANDA). All ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey will be terminated. This follows similar settlements with Teva Pharmaceuticals and Inventia Healthcare Limited, while litigation against Hetero remains ongoing.
Catalyst Pharmaceuticals (NASDAQ:CPRX) has announced a settlement agreement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE® (amifampridine). Under the agreement, Lupin receives a license to market a generic version of FIRDAPSE starting February 25, 2035, pending FDA approval.
The settlement resolves the patent litigation initiated by Catalyst and SERB S.A. in response to Lupin's Abbreviated New Drug Application (ANDA). All ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey will be terminated. This follows similar settlements with Teva Pharmaceuticals and Inventia Life Science, while litigation against Hetero remains ongoing.
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported strong Q2 2025 financial results, with total revenues reaching $146.6 million, up 19.4% year-over-year. The company's portfolio showed broad growth, led by FIRDAPSE® ($84.8M, +9.7% YoY), AGAMREE® ($27.4M, +212.9% YoY), and FYCOMPA® ($34.3M).
First half 2025 revenues totaled $288.0 million, a 30.2% increase over 2024. The company maintains its full-year 2025 revenue guidance of $545-565 million. Q2 GAAP net income was $52.1 million ($0.41 per diluted share), up 27.7% YoY. Catalyst ended Q2 with a strong cash position of $652.8 million and no funded debt.
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) to include important recommendations for Lambert Eaton Myasthenic Syndrome (LEMS).
The updated guidelines now include testing for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies and recommend neurological evaluation for diagnosis. Additionally, amifampridine (FIRDAPSE®) is now recommended as a potential treatment option in consultation with neurology.
Notably, approximately 50% of LEMS cases are associated with underlying malignancy, primarily SCLC, with LEMS observed in 3% of SCLC patients. Internal analysis suggests that 90% of LEMS patients with SCLC may be undiagnosed, highlighting a significant unmet medical need.